Chronic neuropathic pain is often refractory to standard pharmacological treatments. A significant 45% reduction in pain intensity was noted 20 minutes post inhalation (P = .001), turning back to baseline within 90 minutes. Tolerable, lightheadedness, lasting 15-30 minutes and requiring no intervention, was the only reported adverse event.
Link: The Pharmacokinetics, Efficacy, Safety, And Ease Of Use Of A Novel Portable Metered-dose Cannabis Inhaler In Patients With Chronic Neuropathic Pain: A Phase 1a Study
Year: 2014
DOI: 10.3109/15360288.2014.941130
Probability toward demonstrable efficacy of cannabis for treatment of Pain (Neuropathies, in general) according to the results found in this study.
Probability toward demonstrable efficacy of cannabis for treatment of Pain (Chronic Non-Malignant) according to the results found in this study.
In a single-dose, open-label study, patients inhaled a single 15.1 ± 0.1 mg dose of cannabis using the Syqe Inhaler device.